Phase I/IIa safety and dosing trial of intrathecal AVXS 101 in patients with spinal muscular atrophy type 2
Phase of Trial: Phase I/II
Latest Information Update: 14 Jun 2017
At a glance
- Drugs AVXS 101 (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions
- 14 Jun 2017 According to an AveXis media release, this trial is expected to begin in the third quarter of 2017.
- 21 Dec 2016 Planned initiation date changed from 1 Jul 2016 to 1 Apr 2017 as per an AveXis media release which states that the company expects to initiate this trial in the second quarter of 2017.
- 18 Mar 2016 New trial record